Aclasta Research Studies: Osteoporosis
This drug, manufactured by Novartis, is a form of Zoledronate acid which is belongs to the class of drugs called bisphosphonates. The main difference between this drug and other bisphosphonates such as
Fosamax and Boniva is that Aclasta (Reclast) is given as a single infusion once a year and so you are not dealing with a daily, weekly or monthly pill.
There have been a number of scientific studies published about the effectiveness and potential side effects of Aclasta. Since health care providers have been trained to put their confidence in published
scientific studies, I offer you a summary of some of these studies - all on a single page so it will be convenient to print it out a copy for yourself and one for your health care provider, so you can discuss any concerns or questions you might have about taking Aclasta (Reclast).
Specific Aclasta Research Studies for Osteoporosis
Role of Zoledronic acid in the prevention and treatment of
Osteoporosis. Clinical Intervention.. Aging 2011. See full study at: Aclasta Research Studies Osteoporosis.
2. Study by Johann D Ringe: Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis Published in Patient Prevernce Adherence. April 2010.
Side effects: Aclasta Research Studies:
1. Bisphosphonate-induced Severe Hypocalcemia - A Case Report
Won-Seok Do, Jin-Kyung Park, Myung-Il Park, Hyeong-Seok Kim, Sung-Ho Kim, and Duk-Hyun Lee. Bone Metab. 2012 November; 19(2): 139–145.
Bisphosphonate generally seems to be safe, but hypocalcemia may
occasionally develop in the course of bisphosphonate treatment.
Hypocalcemia induced by bisphosphonate is usually mild and asymptomatic,
but unrecognized or poorly treated hypocalcemia can lead to
life-threatening state. A 78-year-old woman who had a history of hip
arthroplasty and intravenous zoledronate treatment for femur neck
fracture was presented to emergency department with altered mental
status. It turned out that her symptom was due to severe hypocalcemia
which was caused by intravenous zoledronate treatment. She also had
renal dysfunction. She was treated by intravenous calcium gluconate and
calcitriol administration. This case supports the need for evaluation of
renal dysfunction, vitamin D deficiency and parathyroid gland
dysfunction before bisphosphonate treatment and accurate monitoring of
plasma calcium and creatinine levels. In addition, vitamin D and calcium
supply during treatment with bisphosphonate is mandatory.
2. Kidney damage when drugs from the bisphosphonate class were administed to patients with cancer was published
in Journal Oncolology Practctice. 2013 March; 9(2): 101–106. YOu can read the abstract and full article by clicking here.
3. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis by Michael Pazianas, Cyrus Cooper, [...], and R Graham G Russell. Published Publsihed in Therapeutic Clinical Risk Management 2010.
Some useful links:
Click here for more information about Aclasta, Reclast
Read about other Osteoporosis, Osteopenia medications